Precise Insights

Advanced Data and AI for Gastric-Esophageal Cancer

On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.

Gastric-Esophageal Cancer

See some of the 1000s of data elements we offer:

Structured Fields

Request a Demo


Structured Fields


Results from variety of patient tests


Oncology practice visits


Tumor-related observations plus vitals, biometrics, pain, and more


Surgeries, radiation, biopsies, imaging, chemotherapy, etc.


Start and end dates, brand vs. generic codes, dosage, duration, and cycles


Disease state, status, severity, and metastasis

Expert Abstraction

Request a Demo


Expert Abstraction


Biomarker testing, results, and timing

Disease Progression

Directly-observed measures of critical endpoints

Adverse Events

Different types of adverse responses


Classification into multiple categories

Enriched Data

Request a Demo


Enriched Data

Cost & Utilization

Adjudicated costs with linked claims data

Safety, Comorbidities

Pre-cancer and claims charge events

Specialty Pharmacy & Hub

Rx acquisition status details

Payer & Formulary

Drug tiers and coverage

Social Determinants

Social and physical environment factors

AI & Model-Based Insights

Request a Demo


AI & Model-Based Insights

Date of Metastasis

Rules-based imputation of date of metastasis

Metastatic Status

Imputation of missing data from unstructured notes

Date of Initial Dx

Imputation of index event

Line of Therapy

Regimen or progression-based drug classes

Patient Adherence

Identify root cause of product switching

Patient Acquisition

Predict factors driving patients’ brand decision

Request Data Count

Explore ConcertAI datasets to see how many patients are in your disease area and meet study criteria.

gastric-esophageal cancer

Research Studies

Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.

gastric-esophageal cancer research study

Treatment Patterns and Outcomes in mGC

The 5-year survival rate for metastatic gastric cancer (mGC) is very low and long remissions are rare. This study examined treatment patterns, outcomes, and HER2 testing over time in mGC patients.

See Full Study

Retrospective Observational Study

  • Progression-free survival
  • Overall survival
Patient Criteria Included:
  • Adults with no concurrent other malignancy
  • Diagnosis between 1/2004 and 7/2011
  • HER2 testing


Eligible patients



Initially diagnosed at Stage IV

Median Progression-free survival by line of therapy

Months – First line


Months – First line

Months – First line


Months – Second line

Months – Third line


Months – Third line


Patients with mGC have PFS and OS similar to clinical trials. Treatment patterns reflect increasing testing of HER2 overexpression.

Annals of Oncology, 2012